FDA issues draft guidance on marketing submissions for AI-enabled medical devices
The Food and Drug Administration issued draft guidance Jan. 6 on marketing submissions and lifecycle management for artificial intelligence-enabled devices. The guidance clarifies differences in terminology between the FDA and the AI device manufacturers and software developers. In addition, it provides recommendations on information needed throughout a product's life cycle for regulation of safety and efficacy.
Related News Articles
Headline
The Department of Health and Human Services announced Sept. 30 that it is doubling its funding for childhood cancer research from $50 million to $100 million…
Headline
The Food and Drug Administration today issued a request for public comment on a series of questions regarding current approaches to evaluating artificial…
Headline
The Office of Science and Technology Policy issued a request for information Sept. 26 seeking feedback on federal regulations that hinder AI development,…
Chairperson's File
Although hospitals and health systems are facing many pressures and challenges, now is the time to truly transform how we care for our patients and communities…
Headline
The Joint Commission and the Coalition for Health AI released guidance Sept. 17 on the responsible use of artificial intelligence in health care, the first…
Chairperson's File
With all of the challenges facing health care — a shrinking workforce population, reduced funding, new technologies and pharmaceuticals — it's no longer an…